October 15, 2020 10:40 AM EDTUpdated 02:18 PM
News Briefing

News brief­ing: Ot­su­ka’s $886M can­cer drug is now a 3-time los­er in PhI­II; Keytru­da ap­proved for clas­si­cal Hodgkin lym­phoma

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Two years af­ter Ot­su­ka un­veiled a flop in their first Phase III tri­al of guadecitabine as a front­line treat­ment, they’re

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

GSK taps Sanofi vet to lead vac­cine R&D; Bris­tol My­ers names head of cor­po­rate af­fairs

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times